The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Risperidone Versus Clozapine in Treatment-Resistant Chronic Schizophrenia: A Randomized Double-Blind Study
Abstract
OBJECTIVE: The purpose of this study was to compare the short-term efficacy and safety of risperidone and clozapine in treatment-resistant chronic schizophrenic patients. METHOD: In a controlled double-blind, multicenter study, 86 inpatients with chronic schizophrenia (DSM-III-R), who were resistant to or intolerant of conventional neuroleptics, were randomly assigned to receive risperidone or clozapine for 8 weeks after a 7-day washout period. After a 1-week dose-titration phase, doses were fixed at 6 mg/day of risperidone and 300 mg/day of clozapine for 1 week and then adjusted according to each patient's response. The final mean doses were 6.4 mg/day of risperidone and 291.2 mg/day of clozapine. Treatment efficacy and safety were evaluated with several well-known rating scales. RESULTS: Both risperidone and clozapine significantly reduced the severity of psychotic symptoms (scores on the Positive and Negative Syndrome Scale and the Clinical Global Impression scale) from baseline, with no significant between-group differences. At endpoint, 67% of the risperidone group and 65% of the clozapine group were clinically improved (reduction of 20% or more in total Positive and Negative Syndrome Scale score). Risperidone appeared to have a faster onset of action. In both groups extrapyramidal symptoms and other adverse events were few, and their severity was generally mild. Neither group showed evidence of a relation between drug plasma concentrations and clinical effectiveness. CONCLUSIONS: Risperidone was well tolerated and as effective as medium doses of clozapine in patients with chronic schizophrenia who had been resistant to or intolerant of conventional neuroleptics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Statistical Power Analysis for the Behavioral Sciences (2nd ed.).
Lachenbruch, P. A., & Cohen, J. (1989) · Journal of the American Statistical Association · doi:10.2307/2290095 · Cited by 37,395
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Glass, G. V., Peckham, P. D., & Sanders, J. R. (1972) · Review of Educational Research · doi:10.3102/00346543042003237 · Cited by 1,826
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
Risperidone in the treatment of schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,193
Reliability and validity of the positive and negative syndrome scale for schizophrenics
Kay, S. R., Opler, L. A., & Lindenmayer, J.-P. (1988) · Psychiatry Research · doi:10.1016/0165-1781(88)90038-8 · Cited by 1,007
CHOUINARD, G., JONES, B., REMINGTON, G., BLOOM, D., ADDINGTON, D., MacEWAN, G. W., LABELLE, A., BEAUCLAIR, L., & ARNOTT, W. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876
Intention-to-Treat Analysis: Implications for Quantitative and Qualitative Research
NEWELL, D. J. (1992) · International Journal of Epidemiology · doi:10.1093/ije/21.5.837 · Cited by 715
Peuskens, J. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.166.6.712 · Cited by 551
Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.1.20 · Cited by 388
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.12.1744 · Cited by 382
Pickar, D. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820050009001 · Cited by 354
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.2.231 · Cited by 322
Huang, M.-L., Peer, A. V., Woestenborghs, R., De Coster, R., Heykants, J., Jansen, A. A. I., Zylicz, Z., Visscher, H. W., & Jonkman, J. H. G. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.146 · Cited by 316
The Risks and Benefits of Clozapine versus Chlorpromazine
CLAGHORN, J., HONIGFELD, G., ABUZZAHAB, F. S., WANG, R., STEINBOOK, R., TUASON, V., & KLERMAN, G. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198712000-00002 · Cited by 301
An overview of the mechanism of action of clozapine.
Meltzer, H. Y. (1994) · PubMed · Cited by 282
Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.179 · Cited by 207
Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.
Potkin, S. G., Bera, R., Gulasekaram, B., Costa, J., Hayes, S., Jin, Y., Richmond, G., Carreon, D., Sitanggan, K., & Gerber, B. (1994) · PubMed · Cited by 206
VanderZwaag, C. J., McGee, M., McEvoy, J. P., Freudenreich, O., Wilson, W. H., & Cooper, T. B. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1579 · Cited by 193
Hasegawa, M., Gutierrez-Esteinou, R., Way, L. E., & Meltzer, H. Y. (1993) · PubMed · Cited by 189
van Beijsterveldt, L. E. C., Geerts, R. J. F., Leysen, J. E., Megens, A. A. H. P., Van den Eynde, H. M. J., Meuldermans, W. E. G., & Heykants, J. J. P. (1994) · Psychopharmacology · doi:10.1007/bf02245444 · Cited by 177
Høyberg, O. J., Fensbo, C., Lingjærde, O., Sloth‐Nielsen, M., Salvesen, I., & Remvig, J. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03480.x · Cited by 176
Grant, S., & Fitton, A. (1994) · Drugs · doi:10.2165/00003495-199448020-00009 · Cited by 173
Patient response and resource management: another view of clozapine treatment of schizophrenia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.6.827 · Cited by 161
Relationship Between Clinical Efficacy and Clozapine Concentrations in Plasma in Schizophrenia
Hasegawa, M., Gutierrez-Esteinou, R., Way, L. E., & Meltzer, H. Y. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199312000-00003 · Cited by 155
Klieser, E., Lehmann, E., Kinzler, E., Wurthmann, C., & HEINRICH, K. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502001-00008 · Cited by 121
Pharmacokinetics of Clozapine and Risperidone: A Review of Recent Literature
Byerly, M., & DeVane, C. L. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199604000-00010 · Cited by 106
HUTTUNEN, M. O., Piepponen, P. T., Rantanen, H., Larmo, I., Nyholm, R., & Raitasuo, V. (1995) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1995.tb09781.x · Cited by 95
Cross-tapering clozapine and risperidone
Koreen, A., Lieberman, J. A., Kronig, M. H., et al. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.11.1690a · Cited by 57
Chouinard, G., Vainer, J. L., Bélanger, M., Turnier, L., Beaudry, P., Roy, J.-Y., & Miller, R. J. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90116-3 · Cited by 43
Efficacy of medium-dose clozapine for treatment-resistant schizophrenia
Kurz, M., Hummer, M., Kurzthaler, I., OBERBAUER, H., & Fleischhacker, W. W. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.11.1690b · Cited by 11
Cited by
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003
Lehman, A. F., Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., Dixon, L. B., Goldberg, R., Green-Paden, L. D., Tenhula, W. N., Boerescu, D., Tek, C., et al. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007071 · Cited by 757
The Role of Serotonin in Antipsychotic Drug Action
Meltzer, H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00046-9 · Cited by 662
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 631
Metadata
- Authors
- Bondolfi, G., Dufour, H., Patris, M., May, J. P., Billeter, U., Eap, C. B., & Baumann, P.
- Venue
- American Journal of Psychiatry
- Published
- 1998-04-01
- Volume
- 155
- Issue
- 4
- Pages
- 499-504
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2040559929
- Cited by
- 283
- References
- 33
- FWCI
- 25.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.